

20. (Cancelled) The method of claim 9 wherein said amount of (R,R '),(R,S ')-amphetaminil sulfate or another pharmaceutically-acceptable salt thereof, substantially free of (S,R '),(S,S')-amphetaminil is administered together with a pharmaceutically-acceptable carrier, diluent, excipient or additive.

21. (Cancelled) The method of claim 9 wherein said condition or disease is narcolepsy, attention deficit hyperactivity disorder (ADHD), depression, Parkinson's disease, cognitive dysfunction, or Alzheimer's disease, renal dysfunction, asthma, obesity, nicotine withdrawal, hypotension, apathy, potentiating activity of a conventional antidepressant, potentiating an opiate for pain control, or reduced energy associated with chemotherapy or radiation therapy.

22. (Cancelled) The method of claim 9 wherein said condition or disease is amenable to treatment 15 by preferential activation of mesolimbic-mediated behavior.

REMARKS

In the office action dated August 25, 2003, the Examiner stated that claims 1-8 were allowable. The Petitioners wish that such claims be allowed and have cancelled claims 9-22.

Sincerely,

A handwritten signature in black ink, appearing to read "Karen Guerrero".

Karen Guerrero
Reg. No. 37,071
Vela Pharmaceuticals, Inc.
609-771-8660 ext. 118